CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

Blood

Volumn 98, Issue 1, 2001, Pages 181-186

  Ibrahim, Sherif ^a   Keating, Michael ^a   Do, Kim Anh ^a   O'Brien, Susan ^a   Huh, Yang O ^a   Jilani, Iman ^a   Lerner, Susan ^a   Kantarjian, Hagop M ^a   Albitar, Maher ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; HEMOGLOBIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN DETERMINATION; HEPATOMEGALY; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LEUKEMIA CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SPLENOMEGALY; SURVIVAL RATE;

EID: 0035412375     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.1.181     Document Type: Article

References (30)

1. Reinherz EL, Kung PC, Goldstein G, et al. Discrete stages of intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T lineage. Proc Natl Acad Sci U S A 1980;77:1588-1592.
2. Deaglio S, Dianzani U, Horenstein AL, et al. Human CD38 ligand: a 120-kDa protein predominantly expressed on endothelial cells. J Immunol. 1996;156:727-734.
3. Mizuguchi M, Otsuka N, Sato M, et al. Neuronal localization of CD38 antigen in human brain. Brain Res. 1995;697:235-240.
4. Kramer G, Steiner G, Edinnger D, et al. High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol. 1995;154:1636-1641.
5. Kato I, Takasawa S, Akabane A, et al. Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta cells: enhanced insulin secretion in CD38-expressing transgenic mice. J Biol Chem. 1995;270:30045-30050.
6. Malavasi J, Funaro A, Roggero S, et al. Human CD38: a glycoprotein in search of a function. Immunol Today. 1994;15:95-97.
7. Oertel J, Oertel B, Schleicher J, et al. Immunophenotyping of blasts in human bone marrow. Ann Hematol. 1996;72:125-129.
8. Funaro A, Spagnoli GC, Ausiello CM, et al. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol. 1990;145:2390-2396.
9. Howard S, Grimaldi JC, Bazan JF, et al. Formation and hydolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993;262:1056-1059.
10. Zupo S, Rugari E, Dono M, Tamborelli G, Malavasi F, Ferrarini M. CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells. Eur J Immunol. 1994;24:1218-1222.
11. Kumagai M, Coustan-Smith E, Murry DJ, et al. Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med. 1995;181:1101-1110.
12. Funaro A, Horenstein AL, Malavasi F. Human CD38: a versatile leukocyte marker with emerging clinical prospective. Fundam Clin Immunol. 1995;3:101-113.
13. Lund FE, Yu N, Kim K-M, et al. Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression. J Immunol. 1996;157:1455-1467.
14. Mehta K, Shahid U, Malavasi F. Human CD38, a cell surface protein with multiple functions. FASEB J. 1996;10:1408-1417.
15. Omede P, Boccadoro M, Gallone G, et al. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood. 1990;76:1375-1379.
16. Koehler M, Behm F, Hancock M, Pui CH. Expression of activation antigens CD38 and CD71 is not clinically important in childhood acute lymphoblastic leukemia. Leukemia. 1993;7:41-45.
17. Mehta K, McQueen T, Mansouri T, et al. Involvement of retinoic acid receptor-α-mediated signaling pathway in induction of CD38 cell-surface antigen. Blood. 1997;89:3607-3614.
18. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
19. Keyhani A, Huh YO, Jendiroba D. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 1999;24:153-159.
20. Ries L, Miller B, Hankey B, et al. SEER cancer statistics review, 1972-1991: tables and graphs. Bethesda, MD: National Cancer Institute; 1994. NIH Publication 94-2789.
21. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B cell disorder and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
22. Cheson BD, Bennet JM, Grever M, et al. National Cancer Institute-sponsored working group for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;12:4990-4997.
23. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
24. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
25. Summerhill RJ, Jackson DG, Galione A. Human lymphocyte antigen CD38 catalyzes the production of cyclic ADP-ribose. FEBS Lett. 1993;335:231-233.
26. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, and Ig superfamily member. J Immunol. 1998;160:395-402.
27. Ausiello CM, Urbani F, LaSala A, et al. CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes. Eur J Immunol. 1995;25:1477-1480.
28. Funaro A, Morra M, Calosso L, et al. Role of the human CD38 molecule in B cell activation and proliferation. Tissue Antigens. 1997;49:7-12.
29. Santos-Argumedo L, Teixira C, Preece G, et al. A B-lymphocyte surface molecule mediating activation and protection from apoptosis via calcium channels. J Immunol. 1993;151:3119-3130.
30. Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies to apoptosis. Blood. 1996;88:1365-1374.